EktaH Shows ~50% Reduction in Post-GLP-1 Weight Rebound with Novel Obesity Treatment and Reports Positive Phase I Data

PRESS RELEASE

EktaH Shows ~50% Reduction in Post-GLP-1 Weight Rebound with Novel Obesity Treatment and Reports Positive Phase I Data

• First-in-class oral mechanism triggers natural satiety hormones, addressing key limitations of GLP-1 therapies
• Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events